english.prescrire.org > Prescrire International > N°128 - June 2012

n°128

June 2012

Issue Contents
Editorial

Free  Compare and contrast

p.144
Sophisticated claims versus patients' reality

New Products


Ipilimumab (New Drug)

p.145-147
Immunostimulant; more assessment needed

Abiraterone (New Drug)

p.147-149
After prostate cancer treatment failure: 4-month survival advantage

Drugs for Alzheimer's disease: best avoided (Reassessment)

p.150
No therapeutic advantage

INN common stem: -terone

p.151

Adverse Effects


Gabapentin and pregabalin: abuse and addiction

p.152-154
Beware excessive use

HPV vaccines and pregnancy: the situation in early 2012

p.154-157
Few data, no particular concerns, but vaccination should be avoided during pregnancy. Active pharmacovigilance must continue

Adverse effects of human papillomavirus vaccines: data available in 2011

p.156-157

Reviews


Treatment of non-localised, non-metastatic rectal cancer

p.158-162
Surgery plus chemoradiotherapy: fewer local recurrences but more adverse effects

Prescrire's advice

p.161
Non-metastatic, non-localised rectal cancer: combining radiotherapy and chemotherapy

Outlook


Key opinion leaders: used as a marketing tool by drug companies

p.163-165
Using reputation to influence decisions and practice: a carefully managed business

Free  Lessons from the other side of the Atlantic

p.165-166
Bevacizumab in breast cancer: approved by EMA, rejected by FDA

Free  International Society of Drug Bulletins (ISDB): fit for the future

p.168

Masthead


Free  Masthead

p.142

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe